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492Objectives: With the introduction of the 31-mm Medtronic CoreValve prosthesis, patients with large aortic
annulus have become eligible for transcatheter aortic valve implantation. The aim of this study was to evaluate
the feasibility, efficacy, and safety of transcatheter aortic valve implantation using the 31-mm Medtronic
CoreValve in patients with severe aortic valve stenosis and large aortic annulus.
Methods: Five institutions in the Netherlands and Italy participated in a retrospective multicenter registry. Clin-
ical, procedural, and imaging data of patients treated with the 31-mmMedtronic CoreValve were retrospectively
collected in accordance with the Valve Academic Research Consortium-2 criteria.
Results: Between August 2011 and November 2012, 47 patients (44 men, mean age 77.6  8.9 years) received
the 31-mm Medtronic CoreValve prosthesis for severe aortic stenosis. Device success (correct positioning of a
single valve with intended performance and no all-cause 30-day mortality) was achieved in 31 patients (66.0%).
Reasons for failing the device success criteria were significant prosthetic aortic regurgitation in 3 patients
(6.4%), second valve implantation in 10 patients (21.2%) (8 cases of malpositioning with high-grade aortic
regurgitation, 1 acute valve dislocation, and 1 delayed valve dislocation), 1 of whom died intrahospital, and
in-hospital mortality in a further 3 patients (6.4%). Peak and mean transaortic gradients decreased significantly
(P<.01). The rate of new pacemaker implantations was 41.7%.
Conclusions: In this retrospective multicenter registry, transcatheter treatment of severe aortic valve stenosis
with the 31-mm Medtronic CoreValve seemed to be challenging, even in experienced hands. If the prosthesis
is properly implanted, it offers adequate valve hemodynamics and proper functioning. (J Thorac Cardiovasc
Surg 2014;148:492-9)Supplemental material is available online.Transcatheter aortic valve implantation (TAVI) is a rapidly
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The Journal of Thoracic and Cardiovascular Surgsevere aortic valve stenosis (AS), significantly improving
survival and quality of life.1,2 Current application of TAVI
is confined to patients with prohibitive or high risk for
surgical aortic valve replacement (SAVR),3 although trials
involving intermediate-risk patients are ongoing.4 Until
recently, another constraint to the practice of TAVI was
the limited range of prosthesis sizes. Patients with severe
AS and large aortic annulus (diameter>27 mm), otherwise
suitable for TAVI, had to be denied transcatheter treatment
because no adequately sized prostheses were available.5
In response to the clinical need for a larger valve prosthesis,
the self-expanding 31-mm Medtronic CoreValve (MCV31;
Medtronic Inc., Minneapolis, Minn) has been developed.
With the introduction of this device, patients with an aortic
annulus dimension up to 29 mm in diameter have become
eligible for TAVI. However, the clinical use of this larger
prosthesis may enhance the procedural challenges. As
only the basal inflow portion of the stent frame has a 31-
mm profile, there is little margin for proper valve place-
ment, rendering valve positioning more decisive to achieve
a good implantation result. Furthermore, the bulky stent
framemay increase the risk of interferencewith mitral valveery c August 2014
Abbreviations and Acronyms
AR ¼ Aortic regurgitation
AS ¼ Aortic valve stenosis
CE ¼ Conformite Europeenne
MSCT ¼ Multislice computer tomography
NYHA ¼ New York Heart Association
SAVR ¼ Surgical aortic valve replacement
TAVI ¼ Transcatheter aortic valve implantation
TEE ¼ transesophageal echocardiography
TTE ¼ transthoracic echocardiography
VARC-2 ¼ Valve Academic Research
Consortium-2
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Dfunction6 and damage to the cardiac conduction system dur-
ing prosthesis deployment.7 So far, no studies regarding
clinical experiences with the MCV31 have been published.
The aim of this study was to investigate the safety, efficacy,
and in-hospital outcomes of TAVI using theMCV31 device.METHODS
For a comprehensive description of the study methodology, please refer
to the online supplementary methods section.
Study Design
This study is an observational, retrospective, multicenter, single-arm
registry. All patients who underwent TAVI for severe aortic valve disease
using the MCV31device were retrospectively identified. Patients selected
for TAVI had been considered unsuitable for SAVR by consensus of a cardi-
ologist and a cardiac surgeon, because of a high predicted operative mor-
tality risk (logistic EuroSCORE >15) or the presence of absolute
contraindications for SAVR (eg, porcelain aorta). Further details on patient
selection have been published previously.3 Patient data were retrospec-
tively collected and documented in a registry. All patients gave informed
consent for the procedure and because of the retrospective nature of the
study design, ethics committee approval was waived.
Device and Implantation Procedure
The MCV31 device received CE (Conformite Europeenne) approval in
August 2011 for transfemoral, transaxillary, and direct aortic implantation,
and has roughly the same design characteristics as its smaller 26-mm and
29-mm predecessors.8 It is only the stent frame inflow portion of the
MCV31 that is larger compared with the 29-mm prosthesis, giving rise to a
pronounced tapering of the inflow portion (Figure 1). Therefore, correct
placement, high enough to allow proper apposition of the enlarged inflow
part to the native aortic valve, is more critical than with the smaller sizes.
The TAVI procedures were performed via the transfemoral, transaxillary,
or direct aortic approach according to the choice of the operators, with stan-
dard access techniques,9,10 under general anesthesia or conscious sedation.
The implantation result (valvular function and location) was assessed by
angiography and echocardiography (either transthoracic echocardiography
[TTE], transesophageal echocardiography [TEE] or intracardiac
echocardiography).
End Point Definitions
In-hospital complications were registered in concordance with the
recently published Valve Academic Research Consortium-2 (VARC-2)
consensus document.11 Device success was defined accordingly as theThe Journal of Thoracic and Caproper implantation of the first valve prosthesis used, with intended perfor-
mance of the prosthetic heart valve (peak aortic flow velocity<3 m/s and
no moderate or severe aortic regurgitation [AR]) and no procedural mortal-
ity (30-day all-cause mortality).
Statistical Analysis
All data were analyzed using IBM SPSS Statistics software version 20
(IBM Corp., Armonk, NY). Results for continuous variables are presented
as means  standard deviation or medians [interquartile range], as consid-
ered appropriate. Categorical variables are reported as counts and percent-
ages. The comparison of continuous variables was done using the Student
t test for unpaired measures or paired t test for repeated measures or their
nonparametric equivalents, the Mann-Whitney U test, and the Wilcoxon
signed ranks test, where appropriate. Categorical variables were analyzed
using the c2 or Fisher exact test.
RESULTS
Between the CE approval of the MCV31in August 2011
and November 2012, 440 patients underwent TAVI at 5
participating institutions in the Netherlands and Italy. All
centers were well experienced in CoreValve implantations
(23, 26, and 29 mm) when the MCV31 was introduced.
Fifty-four patients (12.3%) received the MCV31 device.
Seven patients were excluded from the study because of
off-label use of the prosthesis for pure severe AR without
AS, leaving 47 patients for further analysis. Most of the pa-
tients were male (93.6%); the mean age was 77.6  8.9
years, ranging from 48 to 90 years. Further baseline charac-
teristics are listed in Table 1. The mean aortic annulus diam-
eter (average annulus diameter, as derived from the
maximum and minimum diameters) was 26.4  2.7 mm
on TEE and 27.3  1.6 mm on multislice computer tomog-
raphy (MSCT). Overall left ventricular function was
depressed; 24 patients (44.5%) exhibited a left ventricular
ejection fraction less than 40%. Preprocedural imaging
findings are summarized in Table 2.
Procedural Results
Most patients underwent TAVI through a transfemoral
approach (36 patients), 6 patients were treated via direct
aortic access, and 5 patients underwent a transaxillary pro-
cedure. Acute procedural success (such as that shown in
Figure 2,A) was achieved in 36 patients (76.6%). One intra-
procedural death occurred, caused by ascending aortic
dissection resulting in cardiac tamponade during a transfe-
moral procedure. In 1 patient, the valve prosthesis acutely
embolized to the ascending aorta, which was adequately
managed by snare catheter fixation and relocation of the
prosthesis in the ascending aorta, followed by implantation
of a second valve prosthesis in series (Figure 2, C and D).
Twenty-two patients (46.8%) demonstrated significant
paravalvular AR (grade 2 or higher) immediately after valve
deployment. In 9 of these patients (19.1%), significant par-
avalvular AR occurred as a consequence of incorrect valve
placement, exclusively concerning too low implantations
(Figure 2, B). Seven of these patients required implantationrdiovascular Surgery c Volume 148, Number 2 493
FIGURE 1. Medtronic CoreValve range of prostheses. The CoreValve
third-generation range of prostheses with corresponding stent frame di-
mensions and manufacturer recommendations for MSCT-based sizing.
MSCT, Multislice computer tomography.
TABLE 2. Preprocedural imaging
N ¼ 47
Left ventricular ejection fraction (%) 43.8  14.7
Left ventricular ejection fraction<40%, n (%) 19 (40.4)
Peak aortic transvalvular pressure gradient (mm Hg) 68.5  23.8
Mean aortic transvalvular pressure gradient (mm Hg) 40.1  15.9
Aortic valve orifice area (cm2) 0.69  0.19
Aortic valve regurgitation grade 2 or higher, n (%) 13 (27.7)
Mitral valve regurgitation grade 2 or higher 11 (23.4)
Systolic pulmonary artery pressure (mm Hg) 40.4  10.9
Pulmonary artery hypertension (sPAP  60 mm Hg),
n (%)
4 (8.5)
Aortic annulus diameter on TEE (mm) 26.4  2.7
Aortic annulus average diameter on MSCT (mm)* 27.3  1.6
(range 25.5-30.5)
Percentage of oversizingy 12.2  4.7
sPAP, Systolic pulmonary arterial pressure; TEE, transesophageal echocardiography;
MSCT, multislice computer tomography. *Average diameter calculated using the for-
mula (maximum diameter þ minimum diameter)/2. yAs calculated by the formula
(prosthesis diameter  average diameter on MSCT)/prosthesis diameter.
Acquired Cardiovascular Disease Nijhoff et al
A
C
Dof a second valve prosthesis (TAV-in-TAV) in the same
setting, 1 patient received TAV-in-TAV implantation during
a second procedure, and 1 patient was treated with snare
catheter repositioning only (correct annular placement
was achieved by gently pulling the prosthesis upwards,TABLE 1. Baseline characteristics
Number (%) (N ¼ 47)*
Age, y 77.6  8.9
Female 3 (6.4)
Body mass index, kg/m2 26.7  4.7
Length, cm 173.0  7.5
Weight, kg 80.1  14.0
Body surface area, m2y 1.95  0.19
Diabetes mellitus 12 (25.5)
Hypertension 30 (63.8)
Dyslipidemia 23 (48.9)
COPD 20 (42.6)
Chronic renal disease 20 (42.6)
Glomerular filtration rate, mL/minz 58.6  21.4
Cerebrovascular disease 13 (27.7)
Peripheral artery disease 18 (38.3)
Coronary artery disease 30 (63.8)
Previous myocardial infarction 11 (23.4)
Previous PCI 21 (44.7)
Previous CABG 9 (19.1)
Atrial fibrillation 16 (34.0)
Previous pacemaker implantation 11 (23.4)
Heart rhythm
Sinus rhythm 35 (74.5)
Atrial fibrillation 7 (14.9)
Pacemaker rhythm 5 (10.6)
NYHA functional class III 37 (78.7)
Logistic EuroSCOREx (%) 24.7  23.3
Prohibitive high risk for surgeryk 32 (68.1)
COPD, Chronic obstructive pulmonary disease; PCI, percutaneous coronary inter-
vention; CABG, coronary artery bypass grafting; NYHA, New York Heart Associa-
tion; EuroSCORE, European System for Cardiac Operative Risk Evaluation.
*Results are given as the number (%) except where indicated otherwise. yCalculated
using the Mosteller formula. zEstimated with the Modification of Diet in Renal Dis-
ease formula. xOperative risk as assessed by the EuroSCORE I. kDefined as a logistic
EuroSCORE 15.0%.
494 The Journal of Thoracic and Cardiovascular Surgalthough moderate paravalvular AR persisted). In another
12 patients (25.5%), significant paravalvular AR was suc-
cessfully addressed by postdilatation, because prosthesis
underexpansion was the underlying cause. In the remaining
patient, grade 2 AR did not improve after postdilatation and
was accepted, considering the risk of additional postdilata-
tion. An overview of the procedural variables is given in
Table 3.Echocardiographic Results
All patients underwent TTE before discharge (Table 4),
except for the patient who died during the procedure.
Peak and mean aortic transvalvular pressure gradients
decreased from 68.5  23.8 mm Hg and 40.1  15.9 mm
Hg at baseline to 18.0  6.3 mm Hg and 9.9  3.7 mm
Hg after TAVI, respectively (both P<.001). Predischarge
echocardiography showed AR in 32 patients (71.7%):
mild in 25 patients (54.3%), moderate in 6 patients
(13.0%), and severe in 1 patient (2.2%). The origin of post-
procedural AR was predominantly paravalvular (29 of 32
cases) and less often transvalvular or mixed. The degree
of mitral valve regurgitation (MR) decreased in 8 patients
(17.4%), remained unchanged in 27 patients (57.4%),
worsened in 7 patients (15.2%), and was inadequately as-
sessed in the remaining patients. Worsening of the degree
ofMRwas not related to too low implantations that required
TAV-in-TAV implantation. The change in the distribution of
MR severity before and after TAVI was not significant
(P ¼ .64), the proportion of patients with important MR
(grade 2 or higher) remained the same.In-Hospital Outcome
Therewere 4 in-hospital deaths (8.5%), including the case
of aortic dissection described earlier. One patient, withery c August 2014
FIGURE 2. MCV31 implantation. A, Angiographic result after correct implantation of a 31-mm CoreValve, demonstrating mild paravalvular AR; B,
CoreValve implanted too low with severe periprosthetic AR; C, introduction of a second prosthesis after spontaneous acute embolization of an MCV31
toward the ascending aorta; D, the result after CoreValve implantation in series.
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heart failure induced by pneumonia, despite good valve pros-
thesis function. Another patient died of sequelae of delayed
valve dislocation.On the sixth postprocedural day, thepatient
developed acute cardiac failurewith respiratory insufficiency
requiring intubation. Echocardiography revealed new severe
AR, raising the suspicion of valve dislocation.On emergency
angiography, downward displacement of the CoreValve to-
ward the left ventricular outflow tract was diagnosed
(Figure 3, A-C), which was subsequently treated with TAV-
in-TAVimplantation of a smaller 29-mmCoreValve. Despite
the successful procedure, the patient died of progressive
coma probably caused by hypoxic cerebral damage. In 1 pa-
tient, the cause of death could not be established because
death occurred after unsuccessful resuscitation (pulseless
electrical activity) and no autopsy was performed. No addi-
tional 30-day mortality was reported.
In-hospital re-TAVI was performed in 2 patients. One
patient underwent successful re-TAVI to address significant
AR resulting from a too low implantation during the first
procedure (as mentioned earlier). The other re-TAVI was
performed in the case of delayed valve dislocation
described earlier.The Journal of Thoracic and CaThere were 2 cases of in-hospital stroke (4.2%), both
ischemic events. Of the 36 patients without previous pace-
maker implantation, 15 (41.7%) received a new pacemaker
implantation after TAVI, mainly because of third-degree
atrioventricular block (n ¼ 13). Other pacemaker indica-
tions were sick-sinus syndrome (n ¼ 1) and bradycardia
in atrial fibrillation (n ¼ 1). Further data on in-hospital
outcomes and echocardiographic results are outlined in
Table 4.
Device Success
Device success was achieved in 31 patients (66.0%).
Reasons for not fulfilling the device success criteria were
moderate or severe prosthetic AR in 3 patients (6.4%); sec-
ond valve implantation in 10 patients (21.2%), 1 of whom
died in hospital; and in-hospital mortality in an additional
3 patients (6.4%).
Univariate Analysis
A composite end point for malpositioning (suboptimal
placement of the valve) was created for use in univariate
analysis, including too low implantations requiring second
valve implantation or snare catheter repositioning, andrdiovascular Surgery c Volume 148, Number 2 495
TABLE 3. Procedural data
Number (%)
(N ¼ 47)*
Approach
Transfemoral 36 (76.6)
Direct aortic 6 (12.8)
Transaxillary 5 (10.6)
General anesthesia 11 (23.4)
Fluoroscopy time, minutes (median [interquartile range]) 22.5 [11]
Predilatation 31 (66.0)
Predilatation balloon size, mm 24.6  1.8
Use of stabilizing ventricular pacing 22 (46.8)
Requirement of postdilatation 15 (31.9)
Snare catheter repositioning 1 (2.1)
Conversion to surgery 0
Use of extracorporeal circulation 0
Acute procedural successy 36 (76.6)
Second valve implanted 8 (17.0)
Aortic regurgitation grade 2 or higher 2 (4.3)
Intraprocedural death 1 (2.1)
*Results are given as the number (%) except where indicated otherwise. ySuccessful
implantation of a single valve with proper functioning (correct anatomic position of
the valvewith nomoderate or severe AR present) and the patient leaving the operating
room alive.
Acquired Cardiovascular Disease Nijhoff et al
A
C
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analyzed showed a statistically significant association with
the end point (Table 5). However, predilatation was nonsig-
nificantly more often performed in patients free ofTABLE 4. Outcome and predischarge echocardiographic data
Number (%)
(N ¼ 47)*
In-hospital outcome
Mortality 4 (8.5)
Stroke 2 (4.3)
Myocardial infarction 0
Bleeding 4 (8.6)
Vascular complications 2 (4.3)
New permanent pacemaker implantation 15 (41.7)
Acute kidney injury (stage I)y 7 (14.9)
Delayed valve dislocation 1 (2.1)
Re-TAVI 2 (4.3)
Length of hospital stay, days (median [interquartile
range])
6 [3]
Device success 31 (66.0)
Postprocedural echocardiography (N ¼ 46)
Left ventricular ejection fraction<40% 19 (41.3)
Peak aortic transvalvular pressure gradient, mm Hg 17.4  6.0
Mean aortic transvalvular pressure gradient, mm Hg 9.6  3.8
Aortic regurgitation grade 2 or higher 7 (14.9)
Mitral valve regurgitation grade 2 or higher 10 (21.7)
30-d mortalityz 4 (8.5)
TAVI, Transcatheter aortic valve implantation. *Results are given as the number (%)
except where indicated otherwise. yStage I acute kidney injury: 1.5-1.99 times in-
crease in serum creatinine level compared with baseline, or an absolute increase of
>26.4 mmol/L (Acute Kidney Injury Network classification). zCumulative 30-day
mortality.
496 The Journal of Thoracic and Cardiovascular Surgmalpositioning, with a trend toward more aggressive predi-
latation (with bigger balloons) in this patient group.DISCUSSION
This multicenter registry is the first to publish on clinical
experiences with the MCV31 prosthesis for transcatheter
treatment of severe aortic valve disease in patients with a
large aortic valve annulus (>27 mm). In this registry, these
patients could be further characterized by male gender and
depressed left ventricular function, which is in line with
recent insights on left ventricular dysfunction being an in-
dependent predictor of a large annulus.12 This situation
stresses the importance of the availability of a large-valve
prosthesis, as sufficient oversizing must be provided to
decrease the amount of paravalvular AR in this vulnerable
patient category.13 The MCV31 certainly fills a clinical
need; this registry shows that this larger valve is indicated
in up to 12% of patients suitable for TAVI. In the following
paragraphs, the feasibility, efficacy, and safety of the
MCV31 are discussed.Feasibility
Over the years, transcatheter implantation of the Med-
tronic CoreValve has been performed with increasing suc-
cess, reflecting evolving delivery techniques and operator
experience.8 Several large registries have reported excellent
procedural success rates for third-generation 26-mm and
29-mm CoreValve implantations, reaching nearly
98%.14,15 The results for MCV31 implantations reported
in this study are at odds with this trend, as the need for
second valve implantations had a major impact on the
acute procedural success rate. The incidence of second
CoreValve implantation was high (17.0%) compared with
those reported in the real-world FRANCE2 and Sentinel
registries (3.5% and 2.6%, respectively).14,16 Second
valve implantation was predominantly due to cases of too
low first valve implantation, known to be the most
common type of suboptimal CoreValve deployment
causing significant paravalvular AR.17 Too low implanta-
tion of the prosthesis may lead to severe periprosthetic
leakage, by leaving a gap between the aortic annulus plane
and the pericardial skirt covering the prosthesis stent frame.
TAV-in-TAV implantation is an established technique to
address the problem of a low implant; snare catheter repo-
sitioning may be considered in some cases.17 Device suc-
cess, as defined by VARC-2, decreased further in this
registry as 1 case of delayed valve dislocation was observed,
requiring re-TAVI. No previous reports on delayed disloca-
tion after CoreValve implantation could be found. Core-
Valve dislocation is exclusively reported in the acute
setting, occurring as valve embolization toward the
ascending aorta, immediately after implantation or during
snaring maneuvers.18,19ery c August 2014
FIGURE 3. Delayed valve dislocation. A, Initial MCV31 implanted a lit-
tle low. B, Angiography in the same patient 6 days later; the MCV31
was dislocated toward the left ventricle. C, Angiographic result after a
TAV-in-TAV procedure.
TABLE 5. Univariate analysis
Variable
No malpositioning,
n (%) (N ¼ 35)*
Malpositioning,
n (%) (N ¼ 11)
P
value
Predictors for
malpositioning
Preprocedural
LVEF,%
45.8  14.3 37.9  15.8 .11
Preprocedural grade
AR, median
[interquartile range]
1.0 [1.0] 1.0 [2.0] .57
Average annulus
diameter, mm
27.2  1.6 27.5  1.6 .66
Aortic annulus>29 mm 1 (2.8) 1 (9.1) .42
Percentage of
oversizingy
12.5  4.7 11.2  5.0 .34
Annulus eccentricityz 0.17  0.09 0.13  0.09 .15
Transfemoral approach 26 (74.3) 9 (81.8) 1.00
Predilatation 25 (71.4) 5 (45.5) .15
Balloon size, mm
(median
[interquartile
range])
25.0 [2] 23.0 [3] .14
Balloon to annulus
ratiox
0.92  0.08 0.89  0.05 .45
Stabilizing ventricular
pacing
16 (47.1) 5 (45.5) .92
Effect on outcome
Fluoroscopy time,
minutes (median
[interquartile range])
21 [12] 27 [15] .07
Mortality 2 (5.7) 1 (9.1) 1.00
Stroke 1 (2.8) 1 (9.1) .42
New permanent
pacemaker
implantationjj
11 (39.3) 2 (20.0) .44
Acute kidney injury 4 (11.1) 3 (27.3) .33
Length of hospital stay,
days (median
[interquartile range])
6 [3] 7 [9] .13
LVEF, Left ventricular ejection fraction; AR, aortic regurgitation. *Excluding the pa-
tient who had aortic dissection and died before valve implantation. yCalculated using
the formula ([prosthesis diameter  average diameter]/prosthesis diameter) 3 100.
zCalculated using the formula 1  (minimal diameter/maximal diameter), where
0 indicates the annulus is a perfect circle. xRatio of the balloon diameter and aortic
annulus average diameter; increases as the balloon gets more oversized. jjExcluding
patients with previous pacemaker implantation.
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involved a too low position of the MCV31, occurring either
acutely (initial too low implantation) or in a later phase (de-
layed dislocation toward the left ventricle). This finding
may indicate an operator tendency for too low valve posi-
tioning, although local experience with other CoreValve
sizes is not supportive. Otherwise, it may reflect an intrinsic
property of the MCV31 to creep into the left ventricle dur-
ing deployment and maybe even during the following days,
as stent frame expansion continues. Prosthesis design may
contribute to this phenomenon, as the pronounced taperingrdiovascular Surgery c Volume 148, Number 2 497
Acquired Cardiovascular Disease Nijhoff et al
A
C
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acute angle a, absent in the smaller CoreValves) may act
like an expandable dowel during expansion, pulling the
prosthesis deeper into the left ventricular outflow tract
(Figure 1). Because only the most distal part of the inflow
portion has a diameter of 31 mm, the valve should be im-
planted higher in the annulus than the smaller diameter
valves.
The decision to incorporate too low implantation as well
as valve dislocation in a composite malpositioning end
point was based on the assumption that both complications
may share suboptimal valve positioning as an underlying
mechanism (although valve implantation height was
not quantified). None of the variables used in the univariate
analysis was significantly related to this end point.
However, predilatation was more frequently applied in
patients free of the composite malpositioning end point,
with a modest trend toward more aggressive predilatation
with larger balloons and a larger balloon to annulus ratio.
Depressed left ventricular function may have been an
important argument for omitting predilatation in patients
in the malpositioning group, because impaired left ventric-
ular function may be more sensitive to rapid pacing during
predilatation. Predilatation has been considered a manda-
tory step in TAVI for some time, because it fractures valve
calcifications and increases the effective orifice area,
thereby facilitating an even deployment of the valve pros-
thesis. This concept is not supported by the literature, how-
ever; a feasibility study prospectively omitting predilatation
in CoreValve procedures reported excellent results with
achievement of technical success in 96.7% of 60 patients.20
Multivariate analysis on predictors of malpositioning was
not performed as the sample size was too small to generate
robust data.
Efficacy
Postimplantation valve hemodynamics were good,
considering the substantial significant decrease in both
mean and peak transaortic gradients. None of the patients
had residual stenosis on predischarge TTE. The incidence
and distribution of paravalvular AR were satisfactory,
although postdilatation, snaring and/or second valve im-
plantation were indicated in half of the cases. The second
valve implantations in this study were highly efficacious
for resolving severe paravalvular AR in case of too low im-
plantations, reducing the severity of AR to mild in 7 of 8 pa-
tients. The durability and long-term safety of TAV-in-TAV
procedures is yet to be established, but previously published
1-year outcomes are promising.17
Overall, moderate AR was present in 14.9% of patients
on discharge, an incidence well within the range reported
in a meta-analysis of SAPIEN and CoreValve devices.21
The incidence of moderate AR found in this study can be
considered increased, however, as compared with the498 The Journal of Thoracic and Cardiovascular Surgrecently published results of the Sentinel registry, reporting
postprocedural moderate AR in 9.9% of patients treated
with the CoreValve throughout 2011 and 2012.16
Safety
The rate of in-hospital death was 8.5% in this registry,
which can be regarded as high, as was the 4.2% incidence
of stroke. Delayed valve dislocation seemed to be a harmful
complication, as 1 death was clearly related to the sequelae
of this event. The sole case of intraprocedural mortality in
this registry was caused by aortic dissection, a rare and
dreadful complication often leading to death. Aortic dissec-
tion occurred after failed attempts to cross the native valve
with the delivery catheter before prosthesis deployment,
and therefore cannot be attributed to the MCV31 device.
The absence of myocardial infarction in this study was
not surprising, as reduced MCV31 height may decrease
the already uncommon occurrence of this complication.
The rate of new permanent pacemaker implantation was
at the high end of the range usually observed after Core-
Valve implantation.16,22 This may indicate a trend for
lower device implantation in this cohort, as low
placement is associated with conduction disorders after
CoreValve procedures.23 Alternatively, it may be conceiv-
able that the tapered design of the valve inflow portion leads
to a more localized exertion of radial pressure to the sub-
valvular structures during deployment, thereby increasing
the likelihood of damaging the conduction system. In
contrast to previous data, the incidence of pacemaker im-
plantation was not related to too low first valve placement
requiring TAV-in-TAV implantation.17
No clear unfavorable effect of the MCV31 on mitral
valve function could be discerned, although a benefit on
MR as seen after implantation of the Edwards SAPIEN
valve was absent.24 Despite increased potential for compli-
cations, acutely performed TAV-in-TAV procedures seemed
to be safe in this cohort, because no additional morbidity or
mortality was observed. Only a nonsignificant higher rate of
stage 1 acute kidney injury was noted, probably caused by
the exposure to higher volumes of contrast fluids.
Limitations
The present study is an observational, retrospective,
multicenter, single-arm registry and therefore subject to
all the shortcomings involved in retrospective research.
MSCT and echocardiography images were not evaluated
by a core laboratory, which may have led to heterogeneity
in valve sizing and assessment of paravalvular AR. Because
of the sample size and observational retrospective nature of
the study, no firm conclusions can be drawn on the underly-
ing cause of the low procedural success rates in this registry.
The absence of a control group consisting of patients treated
with smaller CoreValve sizes leaves uncertainty about
whether the results are operator, patient, or prosthesisery c August 2014
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MCV31 implantation in this cohort; for example, no
mandatory predilatation with prespecified balloon size or
use of pacing during implantation was required. Further-
more, this registry is focused on procedural and in-
hospital outcomes and offers no insights into mid-term
and long-term safety and efficacy. Larger series of
MCV31 implantations with longer duration of follow-up,
preferably matched to a cohort of smaller CoreValves, are
necessary for thorough evaluation of this prosthesis.
CONCLUSIONS
In this retrospective multicenter registry, transcatheter
treatment of severe AS with the MCV31 device seemed to
be challenging, even in experienced hands. The valve
should be implanted higher in the annulus than the smaller
(26 and 29 mm) CoreValves, because only the short inflow
portion of the valve has a diameter of 31 mm. Device suc-
cess was low, predominantly because of malpositioning
requiring second valve implantation. The rate of new pace-
maker implantations after the procedure was high. If the
MCV31 is properly implanted, it offers adequate valve he-
modynamics and proper functioning.
The authors would like to thank Wiebren Herder and Alessan-
dro Sticchi for their efforts in data collection.
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SUPPLEMENTARY METHODS
This supplementary methods section provides additional information on
the methodology used in the 31-mm Medtronic CoreValve (MCV31) reg-
istry, discussing patient work-up, device characteristics, transcatheter im-
plantation procedures, and statistical analysis.
Study Design
The study is an observational retrospective multicenter single-arm reg-
istry. All patients who underwent TAVI for severe aortic valve disease using
the MCV31 device were retrospectively identified. Patients selected for
TAVI had been considered unsuitable for SAVR by consensus of a cardiol-
ogist and cardiac surgeon, either because of a high predicted operative mor-
tality risk (logistic EuroSCORE >15) or the presence of absolute
contraindications for SAVR (eg, porcelain aorta). Further details on patient
selection have been published previously.E1
Pre-, intra-, and postprocedural data were retrospectively collected and
documented in a registry. All patients gave informed consent for the proce-
dure and because of the retrospective nature of the study design, ethics
committee approval was waived.
Patient Evaluation
The evaluation of eligibility for TAVI included transthoracic echocardiog-
raphy (TTE), transesophageal echocardiography (TEE), coronary angiog-
raphy, and thoracoabdominal multislice computed tomography (MSCT).
TTEwas performed in all patients beforeTAVI and after the procedure before
discharge. Left ventricular, valvular, and prosthesis function were evaluated
by local experienced echocardiographers incompliancewith dedicatedguide-
lines.E2,E3 TEE could be also be performed, according to the routine of each
participating center, to analyze concomitant mitral valve disease andmeasure
the aortic annulus diameter. MSCT imaging was used to assess the suitability
of vascular entrance sites, as well as to determine aortic annulus dimensions.
Prosthesis sizing was based on MSCT-derived aortic annulus measure-
ments in most patients; in some cases, only TEE measurements were avail-
able. The reliability of these particular measurements and their compliance
with findings from other imaging modalities were considered with close
scrutiny by the interventional teams.
Device
The MCV31 device received CE (Conformite Europeenne) approval in
August 2011 for transfemoral, transaxillary and direct aortic implantation.
It is currently the only valve prosthesis available for transcatheter treatment
of patients with an aortic annulus diameter greater than 27 mm. The
MCV31 has roughly the same design characteristic design as its smaller
26-mm and 29-mm predecessors.E4 It consists of a trileaflet porcine peri-
cardial valve sutured into a nitinol frame. The frame has diamond-
shaped cells with an hourglass-like architecture, in which 3 distinct regions
of radial force can be identified. The outflow portion has low radial force
and is designed to stabilize and center the device in the ascending aorta.
The center portion contains the porcine leaflets and is therefore constrained
to avoid obstruction of the coronary arteries. The inflow portion has high
radial force to exclude the calcified leaflets and maintain intra-annular
anchoring, and is covered with a pericardial skirt to minimize paravalvular
aortic regurgitation (AR) after implantation. It is only this inflow portion
that is actually larger in the 31-mm prosthesis compared with the 29-mm
prosthesis (see article Figure 1), giving rise to a pronounced tapering of
the inflow portion. Therefore, correct placement, high enough to allow
proper apposition of the enlarged inflow part to the native aortic valve, is
more critical than with the smaller sizes. The MCV31 is deployed using
an 18-French delivery catheter with an AccuTrak stability layer (Medtronic
Inc, Minneapolis, Minn).
TAVI
The TAVI procedures were performed via a transfemoral, transaxillary,
or direct aortic approach according to the choice of the operators, using
standard access techniques, under general anesthesia or conscious sedation.
Technical details of the applied approaches have been discussed in detail
elsewhere.E5,E6
Predilatation of the native aortic valvewas left to operator discretion and
preferably performed to facilitate prosthesis implantation. Motivations for
omitting predilatation were poor left ventricular function and mixed dis-
ease with an important regurgitation component. Prosthesis deployment
was performed under fluoroscopic guidance. The use of stabilizing ventric-
ular pacing (100-120 beats per minute) during deployment was at the
discretion of the operator.
After implantation, aortography was used to assess valvular location and
function aswell as patency of the left and right coronary ostia. Valvular func-
tion was thereafter examined by echocardiography (either TTE, TEE, or
intracardiac echocardiography), before the patient left the operating room.
End Point Definitions
In-hospital complications were registered in concordance with the
recently published Valve Academic Research Consortium-2 (VARC-2)
consensus document.E7 In compliance with the VARC-2 definitions, device
success was defined as the proper implantation of the first valve prosthesis
used, with intended performance of the prosthetic heart valve (peak aortic
flow velocity<3m/s and nomoderate or severe AR) and no proceduralmor-
tality (30-day all-cause mortality).E7 In addition, acute procedural success
was defined by the authors as the successful implantation of a single valve
with proper functioning (correct anatomic position of thevalvewith nomod-
erate or severe AR present) and the patient leaving the operating room alive.
Statistical Analysis
All data were analyzed using IBM SPSS Statistics software version 20
(IBM Corp., Armonk, NY). Results for continuous variables were pre-
sented as means  standard deviation or medians [interquartile range],
as considered appropriate. Categorical variables were reported as counts
and percentages. Comparison of continuous variables was done using the
Student t test for unpaired measures or the paired t test for repeated mea-
sures or their nonparametric equivalents, the Mann-Whitney U test and
Wilcoxon signed ranks test, where appropriate. Categorical variables
were analyzed using the c2 or Fisher exact test.
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